Our Mission

We support scientists to push the boundaries of scientific research beyond conventional methods with our innovative and customized devices.

Who we are

DexGen was started by John Chavez and John Herich. Both share a passion for creative solutions that help advance scientific research and improve data.

John Chavez – CEO

John Chavez is CEO of DexGen , bringing over 8 years of leadership and operational expertise in the biotech industry. With a proven track record as a Chief Operating Officer at V&P Scientific, John played a pivotal role in increasing net income and inventing the groundbreaking SpinVessel system. He has extensive experience in streamlining processes, driving business development, and implementing advanced solutions for customers in the laboratory space. John’s strategic insight and innovative approach will fuel DexGen’s growth, making him a key figure in advancing the company’s mission in biotech innovation.

John Herich – CSO

John Herich is the Chief Scientific Officer (CSO) of DexGen, bringing over two decades of experience in drug discovery and lab automation. He has been instrumental in developing high throughput screening systems and designing assays that have led to the approval of major diabetes treatments, including Byetta, Bydureon, and Symlin. With a deep expertise in assay development, robotics, and pharmacology, John has held senior roles at companies like Velia, Novo Nordisk, and Amylin Pharmaceuticals. During his time at Novo Nordisk, he won the Innovation of the Year Award for optimizing GPCR signaling assays. He is also a published author and patent holder, contributing to advancements in diabetes and obesity treatment research.